Konstantinos Vazaios, Εftychia Stavrakaki, Lisette B Vogelezang, Jie Ju, Piotr Waranecki, Dennis S Metselaar, Michaël H Meel, Vera Kemp, Bernadette G van den Hoogen, Rob C Hoeben, E Antonio Chiocca, William F Goins, Andrew Stubbs, Yunlei Li, Marta M Alonso, Friso G Calkoen, Esther Hulleman, Jasper van der Lugt, Martine L M Lamfers
Despite decades of research, the prognosis of high-grade pediatric brain tumors (PBTs) remains dismal; however, recent cases of favorable clinical responses were documented in clinical trials using oncolytic viruses (OVs). In the current study, we employed four different species of OVs: adenovirus Delta24-RGD, herpes simplex virus rQNestin34.5v1, reovirus R124, and the non-virulent Newcastle disease virus rNDV-F0-GFP against three entities of PBTs (high-grade gliomas, atypical teratoid/rhabdoid tumors, and ependymomas) to determine their in vitro efficacy...
June 20, 2024: Mol Ther Oncol